These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 26204670

  • 21. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [Abstract] [Full Text] [Related]

  • 22. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS, Eurich DT, Senthilselvan A, Qiu W, Simpson SH.
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Hardly any hypoglycemias, constant weight--and still cost effective].
    MMW Fortschr Med; 2005 Nov 24; 147(47):72-3. PubMed ID: 16370200
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD.
    J Diabetes Complications; 1994 Nov 24; 8(4):201-3. PubMed ID: 7833494
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide.
    De Leeuw I, De Baere H, Decraene P, Lemmens P, Verhaegen H.
    Diabetologia; 1973 Sep 24; ():364-6. PubMed ID: 4204093
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990].
    Girardin E, Vial T, Pham E, Evreux JC.
    Ann Med Interne (Paris); 1992 Sep 24; 143(1):11-7. PubMed ID: 1605454
    [Abstract] [Full Text] [Related]

  • 35. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2016 Jun 24; 9(6):839-51. PubMed ID: 26924475
    [Abstract] [Full Text] [Related]

  • 36. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG.
    Pharmacogenomics; 2009 Nov 24; 10(11):1781-7. PubMed ID: 19891554
    [Abstract] [Full Text] [Related]

  • 37. Emergency management of oral hypoglycemic drug toxicity.
    Rowden AK, Fasano CJ.
    Emerg Med Clin North Am; 2007 May 24; 25(2):347-56; abstract viii. PubMed ID: 17482024
    [Abstract] [Full Text] [Related]

  • 38. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
    Sobieraj DM, Freyer CW.
    Ann Pharmacother; 2010 May 24; 44(7-8):1334-7. PubMed ID: 20516361
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G, Tavridou A, Elens L, Van Schaik RH, Manolopoulos VG.
    Exp Clin Endocrinol Diabetes; 2014 Jan 24; 122(1):60-3. PubMed ID: 24464600
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.